Deregulated JAK3 mediates growth advantage and hemophagocytosis in extranodal nasal-type natural killer/T-cell lymphoma

Adrien Picod; Suella Martino; Pascale Cervera; Gregory Manuceau; Marc Arca; Monica Wittner; YanYan Zhang; He Liang; Florian Beghi; Eric Solary; Fawzia Louache; Paul Coppo

doi:10.3324/haematol.2021.280349

Deregulated JAK3 mediates growth advantage and hemophagocytosis in extranodal nasal-type natural killer/T-cell lymphoma

Haematologica. 2022 Sep 1;107(9):2218-2225. doi: 10.3324/haematol.2021.280349.

Authors

Affiliations

¹ Inserm U1287, Gustave Roussy, 94805 Villejuif.
² Service d'Anatomopathologie, AP-HP - Sorbonne Université.
³ Inserm U1287, Gustave Roussy, 94805 Villejuif; Université Paris-Sud, F-91405 Orsay; CNRS GDR 3697 MicroNiT.
⁴ Inserm U1287, Gustave Roussy, 94805 Villejuif; Centre de Référence des Microangiopathies Thrombotiques (CNR-MAT), Service d'Hématologie, AP-HP - Sorbonne Université. paul.coppo@aphp.fr.

No abstract available

MeSH terms

Humans
Janus Kinase 3
Killer Cells, Natural / pathology
Lymphohistiocytosis, Hemophagocytic* / diagnosis
Lymphohistiocytosis, Hemophagocytic* / etiology
Lymphohistiocytosis, Hemophagocytic* / pathology
Lymphoma, Extranodal NK-T-Cell*
Lymphoma, T-Cell* / complications
Lymphoma, T-Cell* / genetics
Lymphoma, T-Cell* / pathology
Nose Neoplasms* / pathology

Substances

JAK3 protein, human
Janus Kinase 3

Grants and funding

Funding: This work was funded in part by grants from the following institutions: Fondation pour la Recherche Médicale (FRM), Association pour la Recherche contre le Cancer, and Société d’Hématologie et d’Immunologie Pédiatrique (SHIP).